19-Dec-2025
Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender
TipRanks (Thu, 18-Dec 7:27 AM ET)
Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender
Globe Newswire (Thu, 18-Dec 7:00 AM ET)
Market Chameleon (Mon, 8-Dec 3:22 AM ET)
Globe Newswire (Mon, 8-Dec 7:00 AM ET)
Market Chameleon (Mon, 10-Nov 4:11 AM ET)
Globe Newswire (Mon, 10-Nov 7:00 AM ET)
Globe Newswire (Tue, 4-Nov 7:00 AM ET)
Globe Newswire (Mon, 3-Nov 7:00 AM ET)
Kamada to Present at the Stifel 2025 Healthcare Conference
Globe Newswire (Wed, 29-Oct 7:00 AM ET)
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
Kamada Ltd. - trades on the NASDAQ stock market under the symbol KMDA.
As of December 19, 2025, KMDA stock price climbed to $7.28 with 146,352 million shares trading.
KMDA has a beta of 0.56, meaning it tends to be less sensitive to market movements. KMDA has a correlation of 0.08 to the broad based SPY ETF.
KMDA has a market cap of $418.41 million. This is considered a Small Cap stock.
Last quarter Kamada Ltd. - reported $47 million in Revenue and $.09 earnings per share. This fell short of revenue expectation by $-64 million and missed earnings estimates by -$.01.
In the last 3 years, KMDA traded as high as $9.16 and as low as $3.72.
The top ETF exchange traded funds that KMDA belongs to (by Net Assets): DFIS, DFIC, DISV, DFAX.
KMDA has outperformed the market in the last year with a price return of +27.9% while the SPY ETF gained +18.1%. KMDA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.4% and +2.8%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
KMDA support price is $7.04 and resistance is $7.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KMDA shares will trade within this expected range on the day.
